About Belite bio

About company

Clinical stage biopharma targeting untreatable age-related metabolic disease. Developed from our RBP4 platform technology, Belite Bio™'s lead candidate LBS-008 is in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Designation in the US and EU, as well as Rare Pediatric Disease Designation in the US.